Relmada Therapeutics, Inc. (RLMD)

NASDAQ: RLMD · IEX Real-Time Price · USD
-0.13 (-4.38%)
May 31, 2023, 4:00 PM EDT - Market closed

Company Description

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders.

Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults.

The company was founded in 2004 and is headquartered in Coral Gables, Florida.

Relmada Therapeutics, Inc.
Relmada Therapeutics logo
Country United States
Founded 2004
Industry Biotechnology
Sector Healthcare
Employees 14
CEO Dr. Sergio Traversa M.B.A., MBA, Pharm.D., PharmD

Contact Details

2222 Ponce De Leon Blvd. 3rd Floor
Coral Gables, Florida 33134
United States
Phone 646 876 3459

Stock Details

Ticker Symbol RLMD
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001553643
CUSIP Number 75955J402
ISIN Number US75955J4022
Employer ID 45-5401931
SIC Code 2834

Key Executives

Name Position
Dr. Sergio Traversa M.B.A., MBA, Pharm.D., PharmD Chief Executive Officer and Director
Maged S. Shenouda M.B.A., MBA, R.Ph, R.Ph. Chief Financial Officer
Charles S. Ence CPA, M.B.A. Chief Accounting and Compliance Officer
Dr. Paolo Manfredi M.D., Ph.D. Chief Scientific Officer
Gina DiGuglielmo Vice President and Head of Clinical Operations
Dr. Marco Pappagallo M.D. Chief Medical Officer
John Hixon Head of Commercial
Dr. Richard M. Mangano Consultant

Latest SEC Filings

Date Type Title
May 25, 2023 8-K Current Report
May 15, 2023 8-K Current Report
May 11, 2023 8-K Current Report
May 11, 2023 10-Q Quarterly Report
Apr 19, 2023 8-K Current Report
Mar 31, 2023 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Mar 31, 2023 DEF 14A Other definitive proxy statements
Mar 23, 2023 10-K Annual Report
Mar 23, 2023 8-K Current Report
Mar 13, 2023 8-K Current Report